Medpace Holdings Inc vs Paycom Software Inc — how do they compare? Medpace Holdings Inc trades at $601.96 (market cap $16.90B), while Paycom Software Inc trades at $206.74 (market cap $9.57B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Paycom Software Inc pays a 0.71% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PAYC | |
|---|---|---|
Market Cap | $16.90B | $9.57B |
Sector | Technology | Technology |
52-Week High | $620.59 | $233.89 |
52-Week Low | $393.42 | $113.59 |
Enterprise Value | $16.52B | $10.35B |
Dividend Yield | — | 0.71% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Paycom Software (PAYC) trades at $209.22, down 1.98% over 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings of $2.78 per share, beating estimates, and raised its full-year outlook, driven by 10% revenue growth and AI-driven demand. Fundamentals show robust profitability with a 22.78% net income margin and 41.09% ROE, though valuation multiples like P/E of 22.46 are elevated. Recent news highlights operational efficiency and dividend declarations.
The outlook remains positive given consistent earnings beats and raised guidance, but risks include high valuation and competitive pressures. Analyst consensus is mixed with a $219.22 price target, suggesting moderate upside. Investors should weigh strong fundamentals against potential overvaluation and market sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →